阿斯素,一种新型的葡萄糖原可因,涉及到2型糖尿病
Hongcui Diao1, Xue Li2, Yeqiu Xu3
1Department of Endocrinology, Jinan Central Hospital, Shandong University, Jinan, China.
Journal of diabetes and its complications
|September 28, 2023
概括
阿斯素是一种来自脂肪组织的新型禁食激素,与葡萄糖代谢障碍有关. 这篇评论探讨了阿斯素.
科学领域:
- 内分泌学 在内分泌学.
- 代谢研究研究 代谢研究
- 分子生物学分子生物学
背景情况:
- 阿斯素是一种新发现的激素,在禁食期间由白色脂肪组织分泌.
- 在患有葡萄糖代谢障碍的患者中,经常观察到阿斯素水平升高.
- 纤维素1 (FBN1) 基因编码为阿斯素,源自其最后两个前体.
研究的目的:
- 审查最近关于阿斯素及其与2型糖尿病 (T2DM) 相关的发现.
- 讨论阿斯素影响T2DM发育的机制.
- 为T2DM提供临床诊断和治疗策略的见解.
主要方法:
- 关于阿斯素的最新研究的文献综述.
- 分析阿斯素在葡萄糖平衡,食欲调节,胰岛素分泌和胰岛素敏感性方面的作用.
- 在T2DM中探索阿斯素的多方面的机制.
主要成果:
- 阿斯素涉及到2型糖尿病病变的发生.
- 阿斯素影响关键的代谢途径,包括葡萄糖恒温和胰岛素功能.
- 研究表明,阿司素水平升高与T2DM发展之间存在相关性.
结论:
- 阿斯素代表了2型糖尿病的潜在治疗标.
- 了解阿斯素的机制可以指导开发T2DM的新型诊断和治疗方法.
- 对阿斯素在代谢健康中的作用进行进一步研究是有必要的.
相关概念视频
Glucagon-like Receptor Agonists
348
Incretins include glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP), which stimulate insulin secretion post-meals. In type 2 diabetes, GIP's efficacy is reduced, making GLP-1 a viable drug target. GIP originates from preproGIP.
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
348
Oral Hypoglycemic Agents: α-Glucosidase Inhibitors
196
α-glucosidase inhibitors, including acarbose (Precose), miglitol (Glyset), and voglibose (Voglib) (primarily available in Asia), are drugs that control blood sugar levels by delaying the digestion of starch and disaccharides. They achieve this by inhibiting α-glucosidase enzymes in the intestine, which slow the absorption of carbohydrates in the intestine, which in turn leads to a prolonged release of the glucoregulatory hormone GLP-1 from intestinal L-cells.
Acarbose and miglitol are...
Acarbose and miglitol are...
196
Insulin Secretory Vesicles
5.0K
Insulin secretory vesicles release insulin to stimulate blood glucose uptake and regulate carbohydrate metabolism. When the blood glucose levels increase, glucose enters the pancreatic β-islet cells through glucose transporters. Once inside, glucose is metabolized through glycolysis, the citric acid cycle, and the electron transport chain, producing ATP. This increase in ATP concentration closes ATP-sensitive potassium channels, leading to depolarization of the membrane and the opening of...
5.0K
Insulin: The Receptor and Signaling Pathways
1.3K
Insulin action is mediated through a receptor tyrosine kinase, akin to the IGF-1 receptor. The number of receptors per cell varies significantly, from 40 on erythrocytes to 300,000 on adipocytes and hepatocytes. The insulin receptor consists of linked α/β subunit dimers, forming a heterotetramer glycoprotein with two extracellular α subunits and two β subunits spanning the membrane. The α subunits inhibit the inherent tyrosine kinase activity of the β subunits, but...
1.3K
Insulin: Biosynthesis, Chemistry, and Preparation
415
The endoplasmic reticulum (ER) of pancreatic β-cells synthesizes preproinsulin, which consists of a signal peptide, A and B chains, and a C-peptide. Preproinsulin is then cleaved and folded into proinsulin, which translocates to the Golgi apparatus for sorting and packaging into secretory granules. In these granules, enzymatic clipping generates insulin and C-peptide.
Damage or functional impairment of β-cells inhibits insulin production, leading to diabetes. Diabetes treatment...
Damage or functional impairment of β-cells inhibits insulin production, leading to diabetes. Diabetes treatment...
415
Oral Hypoglycemic Agents: Biguanides and Glitazones
223
Biguanides, particularly metformin (Glucophage), are insulin sensitizers that enhance glucose uptake, thereby reducing insulin resistance. Unlike sulfonylureas, metformin doesn't prompt insulin secretion, which helps to curb hypoglycemia risk. Metformin is beneficial in treating conditions like polycystic ovary syndrome due to its insulin-resistance reduction capability. The drug's primary action involves curtailing hepatic gluconeogenesis, a significant contributor to high blood...
223


